Investigational drug · Phase 2
NG101m
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Glioblastoma Multiforme.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 21, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "NG101m"
First trial start
2027
Jan 1, 2027
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NG101m", any sponsor or status.
Conditions studied
As listed on its trial records.
- Glioblastoma Multiforme
Approved drugs for the same conditions: Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "NG101m" as an intervention, largest first.
- NG101m Adjuvant Therapy in Glioblastoma PatientsNot yet recruiting
NeuGATE TheranosticsIndustry
NCT04373785 · 52 participants (planned) · Start Jan 1, 2027 · Primary completion Jul 30, 2030
Drug: Temozolomide; NG101m · For: Glioblastoma Multiforme
Sites: Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Glioblastoma Multiforme
- LAM561Phase 32 trials
Laminar Pharmaceuticals · Primary Glioblastoma, Glioblastoma Multiforme, High-grade Glioma
- NEO100Perillyl alcoholPhase 22 trials
Neonc Technologies, Inc. · Glioblastoma Multiforme, Residual, Progressive or Recurrent Grade II or III Meningioma
- APL-101Phase 21 trial
Apollomics Inc. · Solid Tumors, Advanced Cancer, Renal Cancer
- BPM31510Phase 21 trial
BPGbio · Glioblastoma, Glioblastoma Multiforme
- ST101Phase 21 trial
Sapience Therapeutics · Glioblastoma, Melanoma Stage IV, Breast Cancer
- VAL-083Phase 21 trial
Kintara Therapeutics, Inc. · Glioma, Glioblastoma, Glioblastoma Multiforme
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.